9 February 2017 - Deborah Wilkes
Archived
Launching an OTC version of the allergy medicine Xyzal (levocetirizine dihydrochloride) should lift Sanofi Consumer Healthcare's sales in the US above EUR1.0 billion (USD1.1 billion) in 2017, according to Alan Main, Sanofi's executive vice president Consumer Healthcare. In 2016, sales in the US reached EUR938 million.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.